Skip to main content

Table 2 PET/CT characteristics according to neoadjuvant CRT regimen

From: Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen

  Standard CRT Extended CRT p
Baseline SUVmax 21.5 ± 11.0 14.8 ± 5.9 0.004
6 weeks SUVmax 7.3 ± 6.3 1.9 ± 1.8 0.001
12 weeks SUVmax 8.4 ± 7.4 1.3 ± 1.9 0.001
Complete Response 18 (18.2 %) 8 (66.7 %) 0.001
∆ %SUVmax variation (6 weeks - baseline) 63.8 ± 24.1 88.1 ± 10.4 0.001
∆ %SUVmax variation (12 weeks - baseline) 57.9 ± 31.5 90.7 ± 13.0 0.001